Scan to get started on Sahi
Rethink Trading
A new age Broking platform with in-house Sahi charts, real-time AI intelligence, and flat ₹10 per order brokerage.
4.5 ★ | 23K+ Ratings | IFTA Startup of the year 2025 | 8M+ downloads
Built for single-screen high performance acrossOptions Buying
Options Buying
Options Buying
Introducing the new & improved Sahi Scalper 2.0
Analyse & execute on a multi-chart layout. Watch the Index and Option Charts, Call & Put, Option Chain, simultaneously without moving an eye from your P&L.
Seamless Options Trading with Powerful Tools
Stay nimble and execute faster than ever before – no matter the screen size.
Trade from Charts, at Sahi Speed
Sahi’s powerful charts are built in-house & give you full control over your trades. Manage risk, optimize entries and exits, and never miss a movement – all without leaving your chart.
Real-Time market intelligence with Sahi AI
Tracks trends, identifies breakouts, highlights the hottest stocks
Analyse, Trade Option Strategies With Confidence
Create strategies that work for you. More control, better results.
Personalized Trading:
Tailor Your Space and Strategy
Personalize your homepage layout to match your trading style. Set up your workspace the way you want it, with just the tools you need.
High Performance Trading
at Incredible Value
Pay only ₹10 per executed order.
Latest news
Acutaas Reports Q2 Net Profit Of ₹1.34 Billion; Raises FY27 Revenue Forecast To 30%
Acutaas Chemicals posted an 83.56% YoY growth in Q2 standalone net profit to ₹134 crore. Driven by robust operational execution and commercial order expansion, the company upgraded its FY27 revenue growth forecast to around 30% (from 25%) and increased its EBITDA margin target to 38–40%.
Maruti Suzuki Approves New Subsidiary Osamu Suzuki Centre Of Excellence Foundation
Maruti Suzuki India Ltd's board has approved setting up a new subsidiary, the Osamu Suzuki Centre Of Excellence Foundation, dedicated to skill development and technical training in manufacturing.
Morepen Laboratories Q2 Consolidated Net Profit Rises to ₹88.9 Crore from ₹41 Crore YoY
Morepen Laboratories' consolidated net profit for Q2 surged 116.83% YoY to ₹88.9 crore from ₹41 crore, reflecting robust operational expansion across its pharmaceutical business.
